Table 2.
Primary, secondary, and exploratory clinical outcomes in high-dose 15 mg/kg IV cohort at week 73 (placebo vs crenezumab; mITT population)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.